Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort

The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomides, Ana Paula Monteiro, de Albuquerque, Cleandro Pires, Santos, Ana Beatriz Vargas, Amorim, Rodrigo Balbino Chaves, Bértolo, Manoel Barros, Júnior, Paulo Louzada, Santos, Isabela Araújo, Giorgi, Rina Dalva Neubarth, Sacilotto, Nathalia de Carvalho, Radominski, Sebastião Cezar, Borghi, Fernanda Maria, Guimarães, Maria Fernanda B. Resende, Pinto, Maria Raquel da Costa, Resende, Gustavo Gomes, Bonfiglioli, Karina Rossi, da Silva, Henrique Carriço, Sauma, Maria de Fátima Lobato da Cunha, Sauma, Marcel Lobato, de Medeiros, Júlia Brito, Pereira, Ivânio Alves, de Castro, Gláucio Ricardo Wernwer, Brenol, Claiton Viegas, Xavier, Ricardo Machado, da Mota, Licia Maria Henrique, Pinheiro, Geraldo da Rocha Castelar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396919/
https://www.ncbi.nlm.nih.gov/pubmed/30822348
http://dx.doi.org/10.1371/journal.pone.0213219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396919/
https://www.ncbi.nlm.nih.gov/pubmed/30822348
http://dx.doi.org/10.1371/journal.pone.0213219

Ejemplares similares